Irafamdastat

Irafamdastat (BMS-986368) (Example 74) is a FAAH and MAGL inhibitor, with IC50s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect[1][2].

Product Specifications

CAS Number

[2244136-58-9]

Product Name Alternative

BMS-986368; CC-97489; ABX-1772

UNSPSC

12352005

Target

FAAH; MAGL

Related Pathways

Metabolic Enzyme/Protease; Neuronal Signaling

Field of Research

Neurological Disease

Purity

98.07

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NC(C1=CC(OC(N2[C@@H](CN(CC2)CC3=CC(OC(F)(F)F)=CC=C3)C)=O)=CN=C1)=O

Molecular Formula

C20H21F3N4O4

Molecular Weight

438.40

References & Citations

[1]Cheryl A. Grice, et al. Dual magl and faah inhibitors. Patent. US20180256566A1|[2]Tim Depmeier, et al. Carbamates with ortho-Substituted O-Phenyl Groups as Dual Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: Inhibitory Potency, Hydrolytic Stability, and QSAR Studies. 2025. ACS Medicinal Chemistry Letters.